DTP is a combination vaccine that protects against three bacterial diseases: diphtheria, tetanus, and pertussis (whooping cough). The original version, first available in 1948, used whole killed bacteria as its pertussis component. That formulation has since been replaced in the United States by DTaP, which uses a purified, acellular version of the pertussis component that causes fewer side effects.
The Three Diseases DTP Targets
Each letter in the name represents a different disease, and all three were serious threats to children before widespread vaccination.
Diphtheria is a bacterial infection that produces a toxin blocking normal protein production in cells. The toxin destroys tissue in the throat and creates a thick membrane that starts out bluish-white and turns greyish-green over a few days. This membrane sticks firmly to the throat lining and can grow large enough to obstruct breathing. Early symptoms look mild: sore throat, low energy, loss of appetite, and a slight fever. But once the toxin enters the bloodstream, it can damage organs throughout the body.
Tetanus comes from bacteria that typically enter the body through a wound. As the bacteria multiply, they release a toxin that interferes with the nerves controlling your muscles. The result is painful, uncontrollable muscle contractions that usually start in the jaw (which is why tetanus is called lockjaw) and progress downward through the neck, abdomen, and limbs. Symptoms worsen over about two weeks and can eventually cause seizure-like full-body spasms, clenched fists, and rigidity severe enough to make breathing difficult.
Pertussis, or whooping cough, moves through three distinct stages. It begins looking like a mild cold with a runny nose, low fever, and occasional cough. Over the next week or two, it escalates into violent coughing fits, sometimes averaging 15 attacks in 24 hours. These paroxysms are followed by a high-pitched “whoop” as the person gasps for air, and they often end in vomiting or exhaustion. The intense coughing phase lasts several weeks before gradually fading, though coughing episodes can recur with later respiratory infections for months.
Whole-Cell DTP vs. Acellular DTaP
The original DTP vaccine contained whole killed pertussis bacteria. It was effective, but it came with a notable rate of side effects. In studies comparing DTP to a version containing only the diphtheria and tetanus components, DTP caused local redness in about 37% of children, swelling in 41%, pain at the injection site in 51%, and fever in roughly 32%. More than half of vaccinated infants experienced fretfulness, and about 3% had episodes of persistent crying.
These reactions, while not dangerous for most children, generated enough concern that researchers developed acellular pertussis vaccines. Instead of using the entire killed bacterium, the acellular version contains only a handful of purified proteins from the pertussis organism. The U.S. made the switch during the 1990s, and no whole-cell DTP vaccines are currently licensed in the country. The newer DTaP causes significantly fewer local and systemic reactions.
The tradeoff is that immunity from DTaP may not last quite as long. Research published in JAMA Pediatrics found that more than 65% of children remain immune to pertussis five years after their last DTaP dose, with protection slowly waning over time. The whole-cell version also produced imperfect but gradually declining immunity, though it was somewhat better at reducing community transmission of pertussis.
Who Gets It and When
The CDC recommends a five-dose DTaP series for all children under age 7. The doses are given at 2 months, 4 months, 6 months, 15 to 18 months, and 4 to 6 years. This schedule spaces the doses to build and reinforce immunity during the years when children are most vulnerable to these diseases.
Because immunity fades over time, older children and adults receive booster shots using a related vaccine called Tdap, which contains lower doses of the diphtheria and pertussis components. The capital letters in these abbreviations indicate higher doses: “DTaP” has full-strength diphtheria and tetanus with acellular pertussis, while “Tdap” has reduced amounts of diphtheria and pertussis, suitable for boosting existing immunity rather than building it from scratch.
Why You Still See “DTP” Used
Even though the whole-cell DTP vaccine is no longer used in the U.S., the abbreviation persists in casual conversation, older medical records, and international contexts. Many countries around the world still use whole-cell pertussis vaccines because they’re less expensive to produce. When someone mentions “the DTP shot” today in an American context, they almost always mean DTaP. The diseases it protects against and the overall vaccination schedule remain the same.